-
Product Insights
NewPeripheral Artery Occlusive Disease (PAOD) Clinical Trial Analysis by Phase, Trial Status, End Point, Sponsor Type and Region, 2023 Update
GlobalData's clinical trial report, “Peripheral Artery Occlusive Disease (PAOD) Clinical Trial Analysis by Trial Phase, Trial Status, Trial Counts, End Points, Status, Sponsor Type, and Top Countries, 2023 Update" provides an overview of Peripheral Artery Occlusive Disease (PAOD) Clinical trials scenario. This report provides top line data relating to the clinical trials on Peripheral Artery Occlusive Disease (PAOD). Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage...
-
Sector Analysis
NewHeart Failure in Major Markets, Disease Management, Epidemiology, Pipeline Assessment, Unmet Needs and Drug Forecast to 2032
Heart Failure Market Report Overview The heart failure market size across the 7MM was valued at $31.9 billion in 2022 and is expected to achieve a CAGR of more than 5% during 2022-2032. The 7MM includes the US, 5EU (France, Germany, Italy, Spain, and the UK), and Japan. GlobalData expects uptake of SGLT2 inhibitors and three first-in-class drugs to be the strongest driver of the total heart failure markets in the 7MM. Heart Failure Market Outlook, 2022-2032 ($ Billion) Buy...
-
Sector Analysis
Heart Failure Epidemiology Analysis and Forecast to 2032
Heart Failure Epidemiology Analysis Report Overview In the 7MM, there were 3,094,817 diagnosed incident cases of heart failure in 2022. The market is expected to grow at an AGR of more than 1% during 2022-2032. The Heart Failure market research report provides an overview of the risk factors, comorbidities, and global and historical epidemiological trends for heart failure in the seven major markets namely the US, France, Germany, Italy, Spain, UK, and Japan. The report also includes a 10-year epidemiology...
-
Sector Analysis
Atrial Fibrillation Market Size, Drug Analysis, Epidemiology, Disease Management, Pipeline Assessment, Unmet Needs and Forecast to 2032
Atrial Fibrillation Market Report Overview Atrial Fibrillation market size across the 8MM was valued at $14.53 billion in 2022 and is expected to decline at a CAGR of more than 1% during 2022-2032. Atrial fibrillation (AF) is clinically defined as an irregular and often rapid heart rhythm caused by the degeneration of electrical impulses in the atria. This disorganized electrical activity of the atria results in accelerated and irregular ventricular activity, loss of atrial mechanical function, and increased risk of...
-
Sector Analysis
Venous Thromboembolism (VTE) Epidemiology Analysis and Forecast to 2032
Venous Thromboembolism (VTE) Market Report Overview In the 7MM, there were 1,469,547 diagnosed incident cases of VTE in 2022. The cases are expected to achieve an AGR of more than 1% during the period 2022-2032. VTE, comprised of deep vein thrombosis (DVT) and pulmonary embolism (PE), is a potentially fatal condition that impedes blood flow by causing blood clots (thrombosis). VTE can occur in men and women of all ages, with children at very low risk, and adults aged 40...
-
Sector Analysis
Atrial Fibrillation Epidemiology Analysis and Forecast to 2032
Atrial Fibrillation Market Report Overview In the 8MM, there were 14,457,906 total prevalent cases of Atrial Fibrillation in 2022. The cases are expected to achieve an AGR of more than 2% during the period 2022-2032. Atrial fibrillation (AF) is characterized by an irregular and often very rapid heart rhythm, or arrhythmia, that can lead to blood clots in the heart. This increases the risk of stroke, heart failure, and other cardiac complications. In AF patients, the normal beating in the...
-
Sector Analysis
Venous Thromboembolism Market Size, Drug Analysis, Epidemiology, Disease Management, Pipeline Assessment, Unmet Needs and Forecast to 2032
Venous Thromboembolism Market Report Overview Venous Thromboembolism market size across the 7MM was valued at $3.57 billion in 2022 and is expected to achieve a CAGR of more than 2% during 2022-2032. The US is the most significant contributor to that revenue due to the large size of the VTE patient population in the US as well as the higher overall price of drugs as compared to the 5EU and Japan. Venous Thromboembolism Market Outlook, 2022-2032 ($ Billion) To gain...
-
Sector Analysis
Myocardial Infarction (MI) Marketed and Pipeline Drugs Assessment, Clinical Trials and Competitive Landscape
Myocardial Infarction Marketed Drugs Overview Myocardial infarction (MI), colloquially known as "heart attack," is caused by decreased or complete cessation of blood flow to a portion of the myocardium. In most cases, this occurs as a result of occlusive coronary atherosclerosis superimposed with a luminal thrombus. MI may be "silent," and go undetected, or it could be a catastrophic event leading to hemodynamic deterioration and sudden death. Most MIs are due to underlying coronary artery disease, the leading cause of...
-
Product Insights
Aneurysm Clinical Trial Analysis by Phase, Trial Status, End Point, Sponsor Type and Region, 2023 Update
Aneurysm Clinical Trials Market Report Overview The aneurysm clinical trial market research report provides an overview of the aneurysm clinical trials scenario. The report provides top-line data relating to the clinical trials on the aneurysm. It also includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. Moreover, it offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status, and sponsor type.
-
Sector Analysis
Heart Failure (HF) Marketed and Pipeline Drugs Assessment, Clinical Trials and Competitive Landscape
Heart Failure (HF) Marketed and Pipeline Drugs Market Report Overview Heart Failure (HF) is a critical clinical condition where certain structural and functional abnormalities in the heart impair its ability to meet systemic circulation. The various causes that contribute to these abnormalities are hypertension, arrythmia, valvular heart disease, and risk factors including high cholesterol, infection, and genetic factors. The Heart Failure (HF) marketed and pipeline drugs market research report includes an assessment of the disease epidemiology, leading marketed products with...
Sign up to receive regular alerts for our latest analysis and reports. No matter your industry focus, you can keep your finger on the pulse with our timely updates.